Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Fennec Pharmaceuticals (FENC) over the last 15 years, with Q3 2025 value amounting to $1.5 million.

  • Fennec Pharmaceuticals' Free Cash Flow rose 16767.91% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.0 million, marking a year-over-year decrease of 13653.79%. This contributed to the annual value of $27.0 million for FY2024, which is 25738.2% up from last year.
  • According to the latest figures from Q3 2025, Fennec Pharmaceuticals' Free Cash Flow is $1.5 million, which was up 16767.91% from -$3.7 million recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Free Cash Flow registered a high of $37.3 million during Q1 2024, and its lowest value of -$8.4 million during Q2 2024.
  • Its 5-year average for Free Cash Flow is -$1.3 million, with a median of -$3.6 million in 2021.
  • The largest annual percentage gain for Fennec Pharmaceuticals' Free Cash Flow in the last 5 years was 76894.39% (2024), contrasted with its biggest fall of 11254.43% (2024).
  • Quarter analysis of 5 years shows Fennec Pharmaceuticals' Free Cash Flow stood at -$3.0 million in 2021, then crashed by 129.95% to -$6.8 million in 2022, then grew by 28.55% to -$4.9 million in 2023, then soared by 69.67% to -$1.5 million in 2024, then skyrocketed by 201.29% to $1.5 million in 2025.
  • Its Free Cash Flow stands at $1.5 million for Q3 2025, versus -$3.7 million for Q2 2025 and -$4.3 million for Q1 2025.